Zobrazeno 1 - 7
of 7
pro vyhledávání: '"B K Skrumsager"'
Publikováno v:
Journal of clinical pharmacology. 43(11)
Ragaglitazar is a novel dual peroxisome proliferator-activated receptor (PPAR) alpha and gamma agonist intended to restore insulin sensitivity and correct diabetic dyslipidemia. These studies assessed single-dose pharmacokinetics and tolerability of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::326776f1f39eaf21266c0ad9715ea29a
https://pubmed.ncbi.nlm.nih.gov/14551179
https://pubmed.ncbi.nlm.nih.gov/14551179
Autor:
Michael Millward, U. Mouritzen, B. K. Skrumsager, Ian D. Davis, Richard F. Kefford, Benjamin Brady, P. E. Kristjansen, Grant A. McArthur
Publikováno v:
Journal of Clinical Oncology. 26:3042-3042
3042 Background: IL-21 has a key role in cancer immunology. We have previously described a phase 1 study of rIL-21 in pts with advanced MM. We now report final clinical results from a phase 2a study in treatment-naive pts with advanced MM. Methods: O
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a149e92360305b3a3c23052c6d341112
https://doi.org/10.1200/jco.2008.26.15_suppl.3042
https://doi.org/10.1200/jco.2008.26.15_suppl.3042
Publikováno v:
International clinical psychopharmacology. 5(4)
GBR 12909 selectively blocks dopamine uptake and its biochemical and pharmacological profiles suggest that it may possess antidepressant activity and be of value in treatment of Parkinson's disease. The tolerance, pharmacokinetics and influence on ps
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ed30d5d2cc03c701575a51439c402e8
https://pubmed.ncbi.nlm.nih.gov/2150527
https://pubmed.ncbi.nlm.nih.gov/2150527
Autor:
Ian D. Davis, Grant A. McArthur, P. E. Kristjansen, Benjamin Brady, B. K. Skrumsager, Michael Millward, Ulrik Mouritzen
Publikováno v:
Journal of Clinical Oncology. 25:3055-3055
3055 Background: rIL-21 is a pleiotropic class I cytokine that activates CD8+ T cells and NK cells. The safety and pharmacologic profile of rIL-21 was characterized in two phase 1 dose escalation studies including patients with MM, performed in Austr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::94fa31dde353a1aa9582160c43f252be
https://doi.org/10.1200/jco.2007.25.18_suppl.3055
https://doi.org/10.1200/jco.2007.25.18_suppl.3055
Publikováno v:
Nordisk Psykiatrisk Tidsskrift. 36:335-339
The selective inhibitor of neuronal 5-hydroxytryptamine uptake, femoxetine, was compared to the tricyclic antidepressant, amitriptyline, in a double-blind randomized clinical study of 45 patients with depressive illness. During the treatment period o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e591906ffc91f6ba0e0635ba66c0849
https://doi.org/10.3109/08039488209102167
https://doi.org/10.3109/08039488209102167
Autor:
B K, Skrumsager, G L, Henderson
Publikováno v:
Proceedings of the Western Pharmacology Society. 20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::601f4f744fef433b44d503d5477ccbf6
https://pubmed.ncbi.nlm.nih.gov/896857
https://pubmed.ncbi.nlm.nih.gov/896857
1. The cardiovascular and anticholinergic effects of femoxetine and amitriptyline were compared with those of placebo in a double-blind cross-over trial in 12 healthy men. The daily doses administered were therapeutic: 600 mg femoxetine and 150 mg am
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2ca2c51663fdd3f51b5a8e17ec62c68
https://europepmc.org/articles/PMC1379833/
https://europepmc.org/articles/PMC1379833/
